Gyre Therapeutics (L9S) Ownership - Who Owns Gyre Therapeutics?
Gyre Therapeutics (L9S) Ownership Overview
- 63.46% Insiders
- 1.56% Mutual Funds
- <0.01% Other Institutional Investors
- 2.24% ETFs
- 32.74% Public Companies and Individual Investors
The ownership structure of Gyre Therapeutics (DE:L9S) stock is a mix of institutional, retail, and individual investors. Approximately 3.80% of the company’s stock is owned by Institutional Investors, 63.46% is owned by Insiders, and 32.74% is owned by Public Companies and Individual Investors.
The ownership structure of Gyre Therapeutics (DE:L9S) stock is a mix of institutional, retail, and individual investors. Approximately 3.80% of the company’s stock is owned by Institutional Investors, 63.46% is owned by Insiders, and 32.74% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
Recent Hedge Fund Trading Activity
| Date | Firm | Activity | Value |
|---|
Top Shareholders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Gni Group Ltd. | 64,005,887 | Insider | 60.36% | 410,981,800 |
| Ying Luo | 2,565,226 | Insider | 2.42% | 16,471,316 |
| Vanguard | 1,550,356 | Institution | 1.46% | 9,954,836 |
| BlackRock, Inc. | 993,943 | Institution | 0.94% | 6,382,108 |
| Vanguard Index Funds | 853,347 | Institution | 0.80% | 5,479,341 |
| Ye Weiguo | 700,000 | Insider | 0.66% | 4,494,700 |
| Ishares | 529,904 | Institution | 0.50% | 3,402,514 |
| Fidelity Concord Street Trust | 241,920 | Institution | 0.23% | 1,553,368 |
| Fidelity Salem Street Trust | 219,720 | Institution | 0.21% | 1,410,822 |
| Schwab | 202,806 | Institution | 0.19% | 1,302,217 |
Top Mutual Fund Holders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Vanguard Index Funds | 853,347 | Institution | 0.80% | 5,479,341 |
| Fidelity Concord Street Trust | 241,920 | Institution | 0.23% | 1,553,368 |
| Fidelity Salem Street Trust | 219,720 | Institution | 0.21% | 1,410,822 |
| Vanguard Scottsdale Funds | 125,278 | Institution | 0.12% | 804,410 |
| Schwab Capital Trust | 65,861 | Institution | 0.06% | 422,893 |
| Goldman Sachs Trust | 47,644 | Institution | 0.04% | 305,922 |
| Tiaa-cref Funds | 24,505 | Institution | 0.02% | 157,347 |
| Dfa Investment Dimensions Group Inc | 19,723 | Institution | 0.02% | 126,641 |
| Vanguard Institutional Index Funds | 12,676 | Institution | 0.01% | 81,393 |
| Vanguard Valley Forge Funds | 10,904 | Institution | 0.01% | 70,015 |
FAQ
Who Owns Gyre Therapeutics (DE:L9S)?
According to the latest TipRanks data, approximately 3.80% of the company's stock is held by institutional investors, 63.46% is held by insiders, and 32.74% is held by public companies and individual investors.
What percentage of Gyre Therapeutics (DE:L9S) stock is held by institutional investors?
According to the latest TipRanks data, approximately 3.80% of Gyre Therapeutics (DE:L9S) stock is held by institutional investors: 1.56% by mutual funds, 2.24% by ETFs and <0.01% by other institutional investors.
What percentage of Gyre Therapeutics (DE:L9S) stock is held by retail investors?
According to the latest TipRanks data, approximately 32.74% of Gyre Therapeutics (DE:L9S) stock is held by public companies and individual investors.
Who owns the most shares of Gyre Therapeutics (DE:L9S)?
GNI Group Ltd. owns the most shares of Gyre Therapeutics (DE:L9S).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
